Pfizer Updates Warning on Adverse Skin Reaction With Bextra (Valdecoxib)

"Pfizer Inc. said on Friday it is sending additional information to healthcare professionals about its arthritis drug Bextra (valdecoxib), a COX-2 inhibitor"

The company also said it reviewed heart risk in rheumatoid arthritis and osteoarthritis patients and saw no increased heart risk in patients taking the Bextra from 6 to 52 weeks. However, in two trials in high-risk coronary artery bypass graft surgery, an increase in heart events was seen in patients taking Bextra alone or in combination with another drug.